Antiviral Resistance Analysis Requested In FDA Draft Guidance
Executive Summary
An analysis of resistance activity associated with antiviral drugs should be conducted prior to the initiation of clinical studies, FDA recommends in a draft guidance released May 25
You may also be interested in...
HIV Drug Development Guidance From FDA Stresses Clinical Resistance Testing
A finalized FDA guidance for antiretroviral drug development emphasizes HIV resistance testing and clinical analysis, rather than preclinical in vitro studies as outlined in the draft guidance. Templates for submitting resistance data on Hepatitis B and C virus also were dropped in the final version
HIV Drug Development Guidance From FDA Stresses Clinical Resistance Testing
A finalized FDA guidance for antiretroviral drug development emphasizes HIV resistance testing and clinical analysis, rather than preclinical in vitro studies as outlined in the draft guidance. Templates for submitting resistance data on Hepatitis B and C virus also were dropped in the final version
Antibacterial Pipeline Hampered By Emerging Resistance From Pharma
Pharma companies may need to place increased emphasis on discovery and development of novel anti-infective agents in order to address the proliferation of multidrug-resistant gram-negative infections